Mind Medicine (MNMD) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MindMed has appointed Gregg A. Pratt, Ph.D., as the Chief Regulatory and Quality Assurance Officer to enhance their regulatory capabilities and expedite progress in launching Phase 3 studies for treatments targeting anxiety and depressive disorders. This move aims to leverage Dr. Pratt’s expertise in securing approvals for groundbreaking psychiatric drugs, including a novel schizophrenia treatment.
For further insights into MNMD stock, check out TipRanks’ Stock Analysis page.